Please assess the completion status of the following clinical trial:

Trial Title: Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Signed and dated written informed consent~* Male or female patient receiving insulin for treatment of T1DM for at least 12 months~* C-peptide \< 1.5 ng/mL~* Age 18 to 65 years~* HbA1c of 7.5% to 10.5%~* Multiple daily injections (MDI) of any type of insulin~* Willing to follow an established and individualized carbohydrate counting method and an insulin administration algorithm~* Body Mass Index of 18.5 to 35.0 kg/m2~* Estimated glomerular filtration rate 60 to 150 mL/min/1.73 m²~* Able and willing to perform study assessments according to investigator's judgement~* Compliance with trial drug administration 80% to 120% during run-in period~* Willing not to take any paracetamol containing drugs during the trial~Exclusion criteria:~* Acute symptomatic urinary tract infection or genital infection, chronic or recurrent cystitis~* History of type 2 diabetes mellitus, maturity onset diabetes of the young (MODY), pancreatic surgery or chronic pancreatitis~* Pancreas, pancreatic islet cells or renal transplant recipient~* Type 1 diabetes mellitus treatment with any other antihyperglycaemic drug except insulin within last 3 months or history of clinically relevant hypersensitivity~* Occurrence of hypoglycaemia that required hospitalization or treatment by an emergency physician or paramedic within last 3 months~* Hypoglycaemia unawareness or frequent episodes of unexplained hypoglycaemia~* Occurrence of diabetic ketoacidosis that required hospitalization or treatment by an emergency physician or paramedic within last 12 months~* History of macrovascular disease including cardiovascular, cerebrovascular and peripheral artery disease~* Autonomic neuropathy with gastroparesis~* Brittle diabetes~* Liver disease~* Treatment with anti-obesity drugs, surgery or aggressive diet regimen leading to unstable body weight~* Treatment with systemic corticosteroids~* Change in dose of thyroid hormones within last 6 weeks or planned change or initiation of such a therapy~* Medical history of cancer or treatment for cancer in the last five years~* Blood dyscrasias or any disorders causing haemolysis or unstable red blood cells~* Alcohol or drug abuse that would interfere with trial participation or any ongoing clinical condition that would jeopardize patient's or site personnel's safety or study compliance~* Intake of an investigational drug in another trial within last 30 days~* Not able to understand and comply with study requirements~* Pre-menopausal women who are nursing or pregnant or of child-bearing potential and are not practising an acceptable method of birth control

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Empagliflozin low (Type: EXPERIMENTAL): Empagliflozin low once daily
- Empagliflozin medium (Type: EXPERIMENTAL): Empagliflozin medium once daily
- Empagliflozin high (Type: EXPERIMENTAL): Empagliflozin high once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete